Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
데이터 추가 비고
원인
There is incorrect activity levels stated on the instructions for use labeling in the leukosure enumeration kit due to the inaccurate activity values provided by the supplier for the raw material ribo-nuclease a type iii-a utilized as a component of the leukosure stain reagent. the activity value for these lots is 3.25ku/ml as compared to 4ku/ml as stated in the product labeling. alteration of the staining enumeration of white blood cells (wbc) in blood component preparation might produce falsely high values of white blood cells in samples with high levels of residual rna. these high values may result in the the blood component being considered inappropriate for use in transfusions thereby reducing the availability of blood for transfusion procedures. the high values may also result in unnecessary reprocessing of the blood component.